Clinical Trials Logo

Treatment clinical trials

View clinical trials related to Treatment.

Filter by:

NCT ID: NCT04348266 Completed - Treatment Clinical Trials

RFA for GIM Treatment

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Use radiofrequency ablation (RFA) for Gastric intestinal metaplasia (GIM) treatment.

NCT ID: NCT04300686 Recruiting - Treatment Clinical Trials

A Pilot Study in Severe Patients With Takayasu Arteritis.

Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.

NCT ID: NCT04299971 Recruiting - Treatment Clinical Trials

Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. Here we tried to classify TAK patients in 3 levels, including mild, moderate, and severe, and prescribe methotrexate and tofacitinib randomly in mild and moderate patients, to observe the relatively better treatment strategy, facilitating better intervention strategy in TAK patients.

NCT ID: NCT04278261 Not yet recruiting - Prostate Cancer Clinical Trials

Comparison H-FIRE and Laparoscopic RP in Treating Men With Localized Prostate Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This trial is comparing the functional and oncological outcomes in treating men with prostate cancer between high-frequency irreversible electroporation and laparoscopic radical prostatectomy.

NCT ID: NCT04126837 Completed - Treatment Clinical Trials

Ankle Trauma: an Emergency Nurse Assessment Study

ATENA
Start date: March 5, 2020
Phase: N/A
Study type: Interventional

The ankle and/or foot injuries incidence is high. Lateral ankle sprains are most common diagnosis, while fractures represent less than 15% of final diagnosis. Ankle and/or foot injuries are associated with significant morbidity in terms of pain and chronic instability. The societal cost of these injuries is significant mainly related to hospital care and sick-leave. In summary ankle and/or foot injuries are very frequent reason for emergency admission. The study hypothesis is that an accelerated nursing care system for traumatized ankle and/or foot patients is feasible and allows patients to be cared for in accordance to current medical recommendations. Such a branch should be followed by a return to work and sports within a time frame consistent with the literature. The duration of patient management in emergency department should be short, less than that observed in a historical cohort. Finally patient satisfaction should be high. In the medium term, the implementation of an accelerated nursing branch for the diagnosis and treatment of ankle and/or foot injuries should contribute to effective care and reduction of over activity in emergency departments.

NCT ID: NCT04062370 Not yet recruiting - Clinical trials for Retinal Vein Occlusion

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

Retinal vein occlusion (RVO) may lead to series of complications including retinal ischemia, macular edema (ME) and induce vision impairment. Intravitreal injection of Ranibizumab (0.5mg) has been proved to be a safe and effective method for the treatment of RVO-ME. In this study, different treatment regimens of Ranibizumab is applied and the effects is observed at 1-6 months to explore the best regimen for RVO. After 6 months, anti-VEGF therapy and/or laser photocoagulation is used to explore whether laser photocoagulation can maintain the therapeutic effect of Ranibizumab or reduce the injection number.

NCT ID: NCT04014387 Recruiting - Treatment Clinical Trials

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

Start date: June 2, 2019
Phase: Phase 4
Study type: Interventional

Prior research has identified profound sleep disruption in individuals with PSP. Not only were these individuals sleeping relatively short periods at night, they were also not recuperating lost sleep during the day. Research also showed the relative preservation of a series of nuclei key in regulating wake and arousal. Investigators believe that therapeutically targeting wake promoting centers with a specific medication will improve sleep quality and overall well-being in PSP. To study this, investigators will be doing a double blind, within subject, remote clinical trial with 3 conditions: suvorexant- which targets a wake promoting system, zolpidem- a standard hypnotic that engages sleep promoting systems, versus placebo. Each condition will last 1 week and will be separated by a 1 week washout period on no sleep medications. Investigators will measure sleep patterns and daytime symptoms to determine if suvorexant, zolpidem, or both medications are safe and effective for treating sleep disturbances and improving overall well-being in PSP.

NCT ID: NCT03974061 Completed - Treatment Clinical Trials

Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

Alcohol consumption at hazardous levels is associated with negative consequences on nearly every step of the HIV care continuum. It is a critical factor in HIV treatment that, if unaddressed, significantly contributes to onward transmission and poor treatment outcomes. Alcohol interventions for people living with HIV (PLWH) in the United States (US) have shown mixed results, and no alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is the failure of these interventions to address the multiple overlapping problems (e.g., comorbid mental health conditions, behavioral health needs) of PLWH who are hazardous drinkers. Innovative alcohol intervention strategies that can have an impact on these multiple behavioral health needs, in a format that can be feasibly delivered in the context of HIV care, are needed. Brief Acceptance and Commitment Therapy (ACT) is a promising intervention for HIV-infected hazardous drinkers. ACT is a transdiagnostic treatment that uses mindfulness skills and values-guided behavioral action plans to impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety, depression, chronic pain, and substance use, making it a promising approach for hazardous drinkers. The overall objective of this application is to adapt an existing brief ACT intervention developed for smoking cessation, and pilot test its feasibility and acceptability for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will be preliminarily associated with decreased alcohol use, improved ART adherence, decreased symptoms of depression, anxiety, and drug use, and increased acceptance-a known mechanism of change in ACT.

NCT ID: NCT03922243 Completed - Treatment Clinical Trials

An Analysis of Dental Treatments Rendered by Undergraduates at Ajman University to Patients From Fujairah, Uae

Start date: August 10, 2018
Phase:
Study type: Observational

A total of 650 dental records were selected from 6000 dental records of patients who had received dental treatment in the Dental Clinic, College of Dentistry, Ajman University(AU)-Fujairah Campus, between academic year,2015/2016 and 2016/2017

NCT ID: NCT03904212 Recruiting - Crohn Disease Clinical Trials

Adipose Tissue Injection in Perianal Fistulas in Crohn´s Disease

Start date: March 27, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized and placebo controlled study investigates the efficacy of injections with freshly harvested autologous adipose tissue in CD patients with complex perianal fistulas refractory to standard surgical and/or medical treatment. 140 CD patients will be included and randomized to either treatment with freshly harvested autologous adipose tissue or placebo (saline). Primary outcome measures are clinical healing 6 months after treatment evaluated by clinical examination and pelvic MRI.